Recon: GSK reviews whether shingles jab reduces dementia risk; Axsome ADHD hits goal in late-stage trial

• Health insurers’ rapid adoption of AI tools is outpacing regulators’ ability to keep watch (STAT)
• Trump picks Susan Monarez to run the CDC (STAT)
• Lawmakers are pushing the HALT Fentanyl Act as the solution to the overdose crisis. Experts warn it will fall short (STAT)
• Axsome's ADHD drug meets main goal in late-stage study (Reuters)
• US FDA Under Makary: MAHA With A Lighter Touch (Pink Sheet)

• GSK studying if best-selling shingles vaccine lowers dementia risk (Reuters) (Pharmaphorum)
• UK weight loss market: M&A opportunities (Pharmaphorum)
• Japan Expands Priority R&D List For Regular Vaccinations (Pink Sheet)
• EU Marketing Approval Gap Between Lilly’s Donamemab and Eisai’s Leqembi Could Narrow (Pink Sheet)
• AstraZeneca, Pfizer rebuked over breaking UK drug marketing rules on LinkedIn use (Fierce Pharma)

• Impatient about cell and gene therapy? Progress in biotech is not always linear (STAT)
• Another immunology biotech emerges as Hillstar takes flight with $67M (Endpoints)
• Ophthalmology startup Character Biosciences gets $93M for genetics-based approach (Endpoints)
• FDA starts review of Sanofi's MS hope tolebrutinib (Pharmaporum)
• Study Shows ‘Insurer-PBMs’ Dominate Medicare Part D, Steer Patients to Their Pharmacies (Pink Sheet)
• Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study (Reuters)
• Activist investor Keith Meister to join Illumina's board (Reuters)

• 5 tips for building a predetermined change control plan (MedTech Dive)
• Urine Test Could Halve Number Of CT Scans For Patients With Kidney Cancer (MedTech Insight)
• Roche’s Bet On Next-Gen Sequencing Poses New Challenge For Illumina’s Market Dominance (MedTech Insight)
• New CLIA Rule Updates Personnel Policies (MedTech Insight)

• Mississippi Becomes Third State to Ban Sale of Cell-Based Meat, Following Florida, Alabama (Food Safety)
• RFK Jr.’s Plan to Test Baby Formula Clashes With FDA Staff Cuts (Bloomberg Law)
• A movement to ban food dyes gains ground across the U.S. (NBC)

• NIH is removing some outside scientific advisers who evaluate agency research (STAT)
• Cuts to Medicaid will set the U.S. back 35 years in dementia care (STAT)
• Three major questions on pharma tariffs Trump claims are on the way (Endpoints)
• AbbVie files trade secrets suit against ADC competitor (Endpoints)
• Mifepristone Filing Supports 2023 US FDA Actions, But Experts Caution Against Overanalyzing (Pink Sheet)
• Schedule III Marijuana Would Still Be Regulated Marijuana (FDA Law Blog)